Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: briskit who wrote (57356)	8/24/1999 4:07:00 PM
From: BRANDYBGOOD	Respond to of 120523

BCRX-was mentioned on CNBC in the last 1/2 hr.

To: briskit who wrote (57356)	8/25/1999 12:11:00 AM
From: Wolff	Respond to of 120523

Glaxo gets FDA approval for flu drug Relenza to be marketed in the U.S. a competitors drug for same items as BCRX. Also same class of drug which has just got FDA approval, they are about 3 years ahead of BCRX in drug deliver to the consumer, and results of BCRX's are not quantified at all even in Phase II they are just subjectively called statisticlly significant which means above the level of 1 or 2 standard deviations, it is a far cry from being called materially significant, or medically significant, it simple means above the level of noise in sampling . URL: cbs.marketwatch.com. By Barbara Kollmeyer, CBS MarketWatch Last Update: 11:07 AM ET Jul 27, 1999 NewsWatch LONDON (CBS.MW) -- Shares in Glaxo Wellcome, the British pharmaceutical giant, were higher on Tuesday after the company said it's received U.S. Food and Drug Administration (FDA) approval for its flu drug, Relenza. The approval follows an extensive regulatory review period after an initial application by Glaxo (GLX: news, msgs) in February 1999. Relenza, known as zanamivir in its generic terms, can now be marketed for the treatment of influenza A and B in the U.S. The news boosted Glaxo shares which rose 79 pence or 5 percent to 16.85 pence towards the end of London's trading day on Tuesday. Relenza is already marketed in Australia and New Zealand and has had widespread approval in the European Union and Switzerland. Analysts said the U.S. marketing of the drug could net the company between $500 million and $1 billion. A spokesman for Glaxo told CBS.MarketWatch.com that it was too early to tell how much money the drug had made in Australia and New Zealand as those launches are in the early stages. But he said patient feedback on the drug so far has been "extremely positive." Relenza is the first of a new class of drugs called neuraminidase inhibitors and is administered using an inhaler. It prevents infection from travelling from one cell to another within the respiratory tract, the chief site of viral replication. The fact that the drug is inhaled and not taken in pill format cuts down on potential side effects, as the drug isn't absorbed into the body, said Glaxo. It said the drug was found to have a high safety profile, equivalent to receiving an inhaler not loaded with the drug, or what is known as a placebo effect. In clinical trials involving more than 6,000 patients, Glaxo said Relenza was found to have cut flu symptoms significantly. Barbara Kollmeyer writes for CBS MarketWatch in London.